Investigating how oxidative stress affects brain function in Alzheimer's disease
Exploring NOX2-Mediated Network Impairment and Neurodegeneration in Alzheimer's Disease
This study is looking at how stress in the body and how the brain uses sugar might affect memory and thinking in people with Alzheimer's, and it hopes to find ways to help improve their brain health using certain medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11052818 on NIH RePORTER |
What this research studies
This research explores the relationship between oxidative stress and brain glucose metabolism in Alzheimer's disease, focusing on how these factors contribute to cognitive decline. It examines the role of pathological proteins like Aβ and hyperphosphorylated Tau, which are associated with Alzheimer's. The study also investigates the impact of network hyperactivity, including subclinical seizures, on cognitive function and aims to develop strategies to mitigate these effects using antiepileptic medications. By understanding these mechanisms, the research seeks to identify potential therapeutic targets for improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or mild cognitive impairment, particularly those experiencing cognitive decline and associated symptoms.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve cognitive function and quality of life for patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in using antiepileptic drugs to improve cognition in Alzheimer's models, indicating that this approach may be effective.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Zilberter, Misha Yuri — J. David Gladstone Institutes
- Study coordinator: Zilberter, Misha Yuri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.